Last edition
News about "HIV treatment "
The data to be presented span Merck’s broad HIV portfolio, including investigational therapies for both treatment and prevention. The presentations will feature new clinical results from Phase 1, 2, and 3 studies evaluating the efficacy, safety, and pharmacokinetics of the company’s next-generation antiviral candidates.
HIV Treatment | 13/10/2025 | By Dineshwori | 139
MPP-ViiV Agreement Expanded: Aurobindo, Cipla and Viatris to Make Generic HIV Drug Cabotegravir
ViiV Healthcare and the Medicines Patent Pool (MPP) have expanded their voluntary licensing agreement for cabotegravir, enabling manufacturers such as Aurobindo, Cipla, and Viatris to develop, manufacture, and supply generic versions for the HIV treatment in 133 countries.
HIV Treatment | 15/07/2025 | By Dineshwori | 233
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy